OncoMatch/Clinical Trials/NCT07082920
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
Is NCT07082920 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies multiple treatments including JNJ-78278343 and JNJ-95298177 for prostatic neoplasms.
Treatment: JNJ-78278343 · JNJ-95298177 · JNJ-87189401 — The purpose of this study is to identify the recommended phase 2 combination dose (RP2CD) of JNJ-78278343 in combination with JNJ-95298177 in Part 1 (Dose confirmation) of the study and to determine how safe and tolerable the RP2CD of JNJ-7827834 and JNJ-95298177 with or without JNJ-87189401 is for treatment of participants with metastatic castration-resistant prostate cancer (mCRPC; a stage of prostate cancer where the cancer has spread beyond the prostate and is resistant to hormonal therapy) in Part 2 (Dose expansion) of study.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Demographics
Prior therapy
Must have received: orchiectomy or androgen deprivation therapy
Prior orchiectomy or medical castration; or, for participants who have not undergone orchiectomy, must be receiving ongoing androgen deprivation therapy with a gonadotropin-releasing hormone (GnRH) analog (agonist or antagonist) prior to the first dose of study drug and must continue this therapy throughout the treatment phase
Cannot have received: KLK2-targeted therapy
Any prior treatment with kallikrein-related peptidase 2 (KLK2)-targeted therapy
Cannot have received: PSMA-targeting therapy
Exception: Parts 2A and 2B only; prior PSMA RLT is allowed in Part 1 and required for Part 2C and Part 2D but last dose must be >3 months prior to the first dose of study treatment
Any prior prostate-specific membrane antigen (PSMA)-targeting therapy (that is [i.e.], participants who received PSMA-targeting radioconjugates are excluded) [Parts 2A and 2B only]. Prior PSMA RLT is allowed in Part 1 and required for Part 2C and Part 2D but last dose must be >3 months prior to the first dose of study treatment
Cannot have received: antibody drug conjugate with microtubule inhibitor payload (auristatins, maytansinoids, tubulysins)
Any prior antibody drug conjugates (ADCs) with microtubule inhibitor payloads (e.g., auristatins, maytansinoids, tubulysins)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Florida Cancer Specialists · Sarasota, Florida
- Columbia University Medical Center · New York, New York
- University Hospitals Cleveland Medical Center · Cleveland, Ohio
- Fred Hutchinson Cancer Center · Seattle, Washington
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07082920 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior KLK2-targeted therapy, PSMA-targeting therapy, antibody drug conjugate with microtubule inhibitor payload disqualifies patients from enrollment.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages